



**Jean-Christophe Hyvert,  
President, Biologics Lonza Group Ltd**

Jean-Christophe Hyvert joined Lonza in 2017 and has served as President of Biologics since 2021. Between 2021 and 2022, he also served as President of Lonza's Cell & Gene Division. Prior to this, he served as Chief Commercial Officer, Lonza Pharma Biotech & Nutrition (LPBN), during which time his business expertise and strong understanding of the segment's financial structure drove LPBN's strategic approach to commercial development and growth. Jean-Christophe originally qualified as a physicist and worked in operations, before moving into a financial role. His experience in operations and finance have provided him with a broad knowledge of both the science and the business sides of Lonza and its divisions.

---

## Career

---

2021 - present	Member of the Executive Committee, Lonza Group Ltd President, Biologics, Lonza Group Ltd
2021 – 2022	President, Cell & Gene, Lonza Group Ltd
2019 – 2020	Chief Commercial Officer, Pharma Biotech & Nutrition Segment, Lonza Group Ltd
2017 – 2019	Vice President, Finance, Pharma & Biotech Segment, Lonza Group Ltd
2016 – 2017	Finance Director ECEMEA, Baxter International
2015 – 2016	Senior Director EMEA Business Development, Baxter International
2013 – 2014	Finance Director, Baxter International
1995 – 2013	Various leadership positions in Finance and Operations at Newell Rubbermaid, Lehman Brothers and Legris (covering Corporate Development, M&A and Supply Chain)

---

## Education

---

- MBA, Northwestern University (USA)
- Master's degree in Physics, INSA, Rennes (FR)
- Exchange student, Technical University of Clausthal (DE)